Atara opens Cal. T-cell operations, manufacturing facility

ATOM features approximately 90,000 square feet dedicated to manufacturing the Company’s off-the-shelf T-cell immunotherapies, as well as additional space for R&D labs and offices for Atara’s Southern California technical operations. The facility provides production capacity to support Atara’s robust pipeline, and its flexible design allows for potential manufacturing expansion of tab-cel, Atara’s most advanced off-the-shelf T-cell immunotherapy. Atara is advancing Phase 3 development of tab-cel, the potential first commercially available off-the-shelf T-cell immunotherapy for the treatment of patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder. The Company recently announced positive long-term outcomes for tab-cel in Phase 2 studies of patients with EBV+ PTLD at the 23rd Congress of European Hematology Association held in Stockholm, Sweden. Atara plans to submit a conditional marketing authorization application in the EU for tab-cel, as well as report initial efficacy results from its Phase 3 program, in the first half of 2019.

https://bit.ly/2K7POFt